Vortioxetine lessens depressive and anxiety symptoms in MDD patients with high anxiety
01 Dec 2016
Vortioxetine 5-20 mg/day lessens depression and anxiety severity in patients with major depressive disorder (MDD) and high levels of anxiety, as observed in a meta-analysis of 10 randomised, placebo-controlled, 6/8-week trials.
Treatment showed favourable safety and tolerability in this population.
Related MIMS Drugs